Table Info

Table 2.

Differences in low- and high-grade astrocytomas among various diagnostic MRI sequences that are currently utilized in astrocytoma diagnoses

Imaging modality	Low-grade astrocytomas	High-grade astrocytomas
MRI	Well-defined homogeneous masses with little or no mass effect, vasogenic edema, or enhancement after contrast administration	Strong contrast enhancement, peritumoral edema (evident on T2-FLAIR sequences), mass effects, heterogeneity, central necrosis, and intratumoral hemorrhage on conventional MRI
SWI	Low ITSS grade	High ITSS grade
DWI	High ADC	Low ADC
PWI	Low rCBV	High rCBV
DCE	High K^trans	Low K^trans
MRS	Low Lip-Lac/Cr, low Cho/Cr	High Lip-Lac/Cr, high Cho/Cr

SWI: susceptibility-weighted imaging; ITSS: intratumoral susceptibility score; DWI: diffusion-weighted imaging; ADC: apparent diffusion coefficient; PWI: perfusion-weighted imaging; rCBV: relative cerebral blood volume; DCE: dynamic contrast enhancement; K^trans: volume transfer coefficient; MRS: magnetic resonance spectroscopy; Lip-Lac/Cr: lipid-lactate to creatine; Cho/Cr: choline to creatine

Declarations

Author contributions

MW: Conceptualization, Writing—original draft, Writing—review & editing. JW: Writing—original draft, Writing—review & editing. JF: Writing—original draft. ED: Writing—original draft. SS: Writing—original draft. BO: Writing—original draft. KC: Writing—original draft. JH: Writing—original draft. BLW: Conceptualization, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Freeman MR. Specification and morphogenesis of astrocytes. Science. 2010;330:774–8. [DOI] [PubMed] [PMC]

Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study. Biosci Rep. 2019;39:BSR20181968. [DOI] [PubMed] [PMC]

Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406. [DOI] [PubMed]

Giovannoni F, Quintana FJ. The role of astrocytes in CNS inflammation. Trends Immunol. 2020;41:805–19. [DOI] [PubMed] [PMC]

Molofsky AV, Deneen B. Astrocyte development: a guide for the perplexed. Glia. 2015;63:1320–9. [DOI] [PubMed]

Batiuk MY, Martirosyan A, Wahis J, de Vin F, Marneffe C, Kusserow C, et al. Identification of region-specific astrocyte subtypes at single cell resolution. Nat Commun. 2020;11:1220. [DOI] [PubMed] [PMC]

Herrero-Navarro Á, Puche-Aroca L, Moreno-Juan V, Sempere-Ferràndez A, Espinosa A, Susín R, et al. Astrocytes and neurons share region-specific transcriptional signatures that confer regional identity to neuronal reprogramming. Sci Adv. 2021;7:eabe8978. [DOI] [PubMed] [PMC]

Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007;25:1111–39. [DOI] [PubMed]

Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3–9. [DOI] [PubMed] [PMC]

10.

Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50. [DOI] [PubMed]

11.

Chaulagain D, Smolanka V, Smolanka A, Munakomi S, Havryliv T. The role of extent of resection on the prognosis of low-grade astrocytoma: a systematic review and meta-analysis. Egypt J Neurosurg. 2022;37:19. [DOI]

12.

Johnson DR, Galanis E. Medical management of high-grade astrocytoma: current and emerging therapies. Semin Oncol. 2014;41:511–22. [DOI] [PubMed]

13.

Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108. [DOI] [PubMed]

14.

Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro Oncol. 2017;19:1553–64. [DOI] [PubMed] [PMC]

15.

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4:1254–62. [DOI] [PubMed] [PMC]

16.

Costa AR, Lança de Oliveira M, Cruz I, Gonçalves I, Cascalheira JF, Santos CRA. The sex bias of cancer. Trends Endocrinol Metab. 2020;31:785–99. [DOI] [PubMed]

17.

Bello-Alvarez C, Camacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones. Biol Sex Differ. 2021;12:28. [DOI] [PubMed] [PMC]

18.

Carteri RB, Kopczynski A, Rodolphi MS, Strogulski NR, Sartor M, Feldmann M, et al. Testosterone administration after traumatic brain injury reduces mitochondrial dysfunction and neurodegeneration. J Neurotrauma. 2019;36:2246–59. [DOI] [PubMed] [PMC]

19.

Rodríguez-Lozano DC, Velázquez-Vázquez DE, Del Moral-Morales Á, Camacho-Árroyo I. Dihydrotestosterone induces proliferation, migration, and invasion of human glioblastoma cell lines. Onco Targets Ther. 2020;13:8813–23. [DOI] [PubMed] [PMC]

20.

Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero Cazares H. Sex-specific differences in glioblastoma. Cells. 2021;10:1783. [DOI] [PubMed] [PMC]

21.

Davis ME. Epidemiology and overview of gliomas. Semin Oncol Nurs. 2018;34:420–9. [DOI] [PubMed]

22.

Tabash MA. Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis. J Neurol Sci. 2019;400:148–52. [DOI] [PubMed]

23.

Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. [DOI] [PubMed]

24.

Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci. 2018;47:103–10. [DOI] [PubMed]

25.

Karlsson P, Holmberg E, Lundell M, Mattsson A, Holm LE, Wallgren A. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat Res. 1998;150:357–64. [DOI] [PubMed]

26.

Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al.; Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113:1953–68. [DOI] [PubMed] [PMC]

27.

Chen YH, Gutmann DH. The molecular and cell biology of pediatric low-grade gliomas. Oncogene. 2014;33:2019–26. [DOI] [PubMed]

28.

Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell. 2009;15:45–56. Erratum in: Cancer Cell. 2009;15:240. [DOI] [PubMed] [PMC]

29.

Carlos-Escalante JÁ, Gómez-Flores-Ramos L, Bian X, Perdomo-Pantoja Á, de Ándrade KC, Mejía-Pérez SI, et al. Landscape of germline genetic variants in AGT, MGMT, and TP53 in Mexican adult patients with astrocytoma. Cell Mol Neurobiol. 2021;41:1285–97. [DOI] [PubMed]

30.

Alentorn A, Labussière M, Sanson M, Delattre JY, Hoang-Xuan K, Idbaih Á. Genetics and brain gliomas. Presse Med. 2013;42:806–13. French.

31.

Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol Clin. 2002;20:841–65. [DOI] [PubMed]

32.

Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41:143–9. [DOI] [PubMed]

33.

Stern J, Jakobiec FA, Housepian EM. The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthalmol. 1980;98:505–11. [DOI] [PubMed]

34.

Kirkpatrick P. Neurosurgical management of aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2000;68:538E. [DOI] [PubMed] [PMC]

35.

Perdomo-Pantoja A, Mejía-Pérez SI, Reynoso-Noverón N, Gómez-Flores-Ramos L, Soto-Reyes E, Sánchez-Correa TE, et al. Ángiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma. PLoS One. 2018;13:e0206590. [DOI] [PubMed] [PMC]

36.

Wang T, Sun Y, Xiong Z, Wu J, Ding X, Guo X, et al. Association of ST6GAL1 and CYP19A1 polymorphisms in the 3’-UTR with astrocytoma risk and prognosis in a Chinese Han population. BMC Cancer. 2021;21:391. [DOI] [PubMed] [PMC]

37.

The genetics of cancer [Internet]. Credit the National Cancer Institute as the source; [cited 2022 Aug 10]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics

38.

Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13. [DOI] [PubMed]

39.

Guha T, Malkin D. Inherited TP53 mutations and the Li-Fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;7:a026187. [DOI] [PubMed] [PMC]

40.

IDH1 isocitrate dehydrogenase (NADP(+)) 1 [ Homo sapiens (human) ] [Internet]. Courtesy of the National Library of Medicine; [cited 2022 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/gene/3417

41.

IDH2 isocitrate dehydrogenase (NADP(+)) 2 [ Homo sapiens (human) ] [Internet]. Courtesy of the National Library of Medicine; [cited 2022 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/gene/3418

42.

Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–80. [DOI] [PubMed] [PMC]

43.

Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932–41. [DOI] [PubMed] [PMC]

44.

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44. [DOI] [PubMed] [PMC]

45.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597–604. [DOI] [PubMed]

46.

Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82. [DOI] [PubMed]

47.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707–18. [DOI] [PubMed]

48.

MGMT O-6-methylguanine-DNA methyltransferase [ Homo sapiens (human) ] [Internet]. Courtesy of the National Library of Medicine; [cited 2022 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/gene/4255

49.

Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876:188616. [DOI] [PubMed]

50.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. [DOI] [PubMed]

51.

Minniti G, Scaringi C, Arcella A, Lanzetta G, Di Stefano D, Scarpino S, et al. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol. 2014;118:377–83. [DOI] [PubMed]

52.

Hosoya T, Takahashi M, Honda-Kitahara M, Miyakita Y, Ohno M, Yanagisawa S, et al. MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. J Neurooncol. 2022;157:561–71. [DOI] [PubMed] [PMC]

53.

Servier Medical Art [Internet]. [cited 2022 Jan 28]. Available from: https://smart.servier.com

54.

Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. 2013;33:13–21. [DOI] [PubMed] [PMC]

55.

Peruzzi P, Prabhu V. Astrocytoma tumors [Internet]. Rolling Meadows: American Association of Neurological Surgeons; 2023 [cited 2022 Aug 10]. Available from: https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Astrocytoma-Tumors

56.

Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer. 2018;119:1171–81. [DOI] [PubMed] [PMC]

57.

Didenko VV, Ngo HN, Minchew C, Baskin DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg. 2002;96:580–4. [DOI] [PubMed] [PMC]

58.

Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989;143:3222–9. [DOI] [PubMed]

59.

Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, et al. Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Front Immunol. 2020;11:582106. [DOI] [PubMed] [PMC]

60.

Zhang H, Liao J, Zhang X, Zhao E, Liang X, Luo S, et al. Sex difference of mutation clonality in diffuse glioma evolution. Neuro Oncol. 2019;21:201–13. [DOI] [PubMed] [PMC]

61.

Claus EB, Cannataro VL, Gaffney SG, Townsend JP. Environmental and sex-specific molecular signatures of glioma causation. Neuro Oncol. 2022;24:29–36. Erratum in: Neuro Oncol. 2022;24:2012. [DOI] [PubMed] [PMC]

62.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. [DOI] [PubMed]

63.

Mamelak AN, Prados MD, Obana WG, Cogen PH, Edwards MS. Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg. 1994;81:24–30. [DOI] [PubMed]

64.

Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results program of the National Cancer Institute. J Neurooncol. 2012;108:187–93. [DOI] [PubMed]

65.

Dirven CM, Mooij JJ, Molenaar WM. Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature. Childs Nerv Syst. 1997;13:17–23. [DOI] [PubMed]

66.

Komotar RJ, Burger PC, Carson BS, Brem H, Olivi A, Goldthwaite PT, et al. Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery. 2004;54:72–80. [DOI] [PubMed]

67.

Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, Paz Paredes A, et al. Pilocytic astrocytomas in children: prognostic factors—a retrospective study of 80 cases. Neurosurgery. 2003;53:544–55. [DOI] [PubMed]

68.

Bornhorst M, Frappaz D, Packer RJ. Chapter 20 - Pilocytic astrocytomas. In: Berger MS, Weller M, editors. Handb Clin Neurol. Elsevier; 2016. pp. 329–44. [DOI] [PubMed]

69.

Mair MJ, Wöhrer A, Furtner J, Simonovska A, Kiesel B, Oberndorfer S, et al. Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. J Neurooncol. 2020;148:187–98. [DOI] [PubMed] [PMC]

70.

Tahiri Elousrouti L, Lamchahab M, Bougtoub N, Elfatemi H, Chbani L, Harmouch T, et al. Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. J Med Case Rep. 2016;10:35. [DOI] [PubMed] [PMC]

71.

Campen CJ, Porter BE. Subependymal giant cell astrocytoma (SEGA) treatment update. Curr Treat Options Neurol. 2011;13:380–5. [DOI] [PubMed] [PMC]

72.

Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8:30. [DOI] [PubMed] [PMC]

73.

Liu S, Liu X, Zhuang W. Prognostic factors associated with survival in patients with diffuse astrocytoma. Front Surg. 2021;8:712350. [DOI] [PubMed] [PMC]

74.

Chiang J, Harreld JH, Tinkle CL, Moreira DC, Li X, Acharya S, et al. A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol. 2019;138:1091–2. [DOI] [PubMed] [PMC]

75.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51. [DOI] [PubMed] [PMC]

76.

Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2:395–403. [DOI] [PubMed]

77.

Lind-Landström T, Habberstad AH, Sundstrøm S, Torp SH. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012;5:152–8. [PubMed] [PMC]

78.

Zhang F, Liu Y, Zhang Z, Li J, Wan Y, Zhang L, et al. 5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Sci Rep. 2016;6:20882. [DOI] [PubMed] [PMC]

79.

Chen JR, Yao Y, Xu HZ, Qin ZY. Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore). 2016;95:e2583. [DOI] [PubMed] [PMC]

80.

Cancer Genome Atlas Research Network; Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98. [DOI] [PubMed] [PMC]

81.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. 2012;118:452–60. [DOI] [PubMed]

82.

Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol. 2012;109:15–22. [DOI] [PubMed]

83.

Dong X, Noorbakhsh A, Hirshman BR, Zhou T, Tang JA, Chang DC, et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neurooncol Pract. 2016;3:29–38. [DOI] [PubMed] [PMC]

84.

Shaikh N, Brahmbhatt N, Kruser TJ, Kam KL, Appin CL, Wadhwani N, et al. Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol. 2019;8:CNS39. [DOI] [PubMed] [PMC]

85.

Lim S, Kim JH, Kim SA, Park ES, Ra YS, Kim CJ. Prognostic factors and therapeutic outcomes in 22 patients with pleomorphic xanthoastrocytoma. J Korean Neurosurg Soc. 2013;53:281–7. [DOI] [PubMed] [PMC]

86.

Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8:253–60. [DOI] [PubMed] [PMC]

87.

Lakomy R, Kazda T, Selingerova I, Poprach A, Pospisil P, Belanova R, et al. Real-world evidence in glioblastoma: Stupp’s regimen after a decade. Front Oncol. 2020;10:840. [DOI] [PubMed] [PMC]

88.

Christians A, Adel-Horowski A, Banan R, Lehmann U, Bartels S, Behling F, et al. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathol Commun. 2019;7:156. [DOI] [PubMed] [PMC]

89.

Yang W, Xu T, Garzon-Muvdi T, Jiang C, Huang J, Chaichana KL. Survival of ventricular and periventricular high-grade gliomas: a Surveillance, Epidemiology, and End Results program-based study. World Neurosurg. 2018;111:e323–34. [DOI] [PubMed]

90.

Fyllingen EH, Bø LE, Reinertsen I, Jakola AS, Sagberg LM, Berntsen EM, et al. Survival of glioblastoma in relation to tumor location: a statistical tumor atlas of a population-based cohort. Acta Neurochir (Wien). 2021;163:1895–905. [DOI] [PubMed] [PMC]

91.

Osborn AG, Louis DN, Poussaint TY, Linscott LL, Salzman KL. The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know. AJNR Am J Neuroradiol. 2022;43:928–37. [DOI] [PubMed]

92.

McNamara C, Mankad K, Thust S, Dixon L, Limback-Stanic C, D’Arco F, et al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology. 2022;64:1919–50. [DOI] [PubMed]

93.

Mechtler L. Neuroimaging in neuro-oncology. Neurol Clin. 2009;27:171–201. [DOI] [PubMed]

94.

Pierallini A, Bonamini M, Bozzao A, Pantano P, Stefano DD, Ferone E, et al. Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. Eur Radiol. 1997;7:395–9. [DOI] [PubMed]

95.

Tervonen O, Forbes G, Scheithauer BW, Dietz MJ. Diffuse “fibrillary” astrocytomas: correlation of MRI features with histopathologic parameters and tumor grade. Neuroradiology. 1992;34:173–8. [DOI] [PubMed]

96.

Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34:463–9. [DOI] [PubMed]

97.

Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, Palmer JD, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017;6:40. [DOI] [PubMed]

98.

Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22:1081–8. [PubMed] [PMC]

99.

de Fatima Vasco Aragao M, Law M, Batista de Almeida D, Fatterpekar G, Delman B, Bader AS, et al. Comparison of perfusion, diffusion, and MR spectroscopy between low-grade enhancing pilocytic astrocytomas and high-grade astrocytomas. AJNR Am J Neuroradiol. 2014;35:1495–502. [DOI] [PubMed] [PMC]

100.

Abdullah KG, Lubelski D, Nucifora PG, Brem S. Use of diffusion tensor imaging in glioma resection. Neurosurg Focus. 2013;34:E1. [DOI] [PubMed]

101.

Lee SK. Diffusion tensor and perfusion imaging of brain tumors in high-field MR imaging. Neuroimaging Clin N Am. 2012;22:123–34. [DOI] [PubMed]

102.

Kim R, Choi SH, Yun TJ, Lee ST, Park CK, Kim TM, et al. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Eur Radiol. 2017;27:1176–85. [DOI] [PubMed]

103.

Chakravorty A, Steel T, Chaganti J. Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours. Neuroradiol J. 2015;28:574–83. [DOI] [PubMed] [PMC]

104.

Bulakbaşı N, Paksoy Y. Ádvanced imaging in adult diffusely infiltrating low-grade gliomas. Insights Imaging. 2019;10:122. Erratum in: Insights Imaging. 2020;11:57. [DOI] [PubMed] [PMC]

105.

Porto L, Kieslich M, Franz K, Lehrbecher T, Vlaho S, Pilatus U, et al. Spectroscopy of untreated pilocytic astrocytomas: do children and adults share some metabolic features in addition to their morphologic similarities? Childs Nerv Syst. 2010;26:801–6. [DOI] [PubMed]

106.

Krouwer HG, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg. 1991;74:399–406. [DOI] [PubMed]

107.

Simkin PM, Yang N, Tsui A, Kalnins RM, Fitt G, Gaillard F. Magnetic resonance imaging features of gemistocytic astrocytoma. J Med Imaging Radiat Oncol. 2016;60:733–40. [DOI] [PubMed]

108.

Joyner DA, Garrett J, Batchala PP, Rama B, Ravicz JR, Patrie JT, et al. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma. Neuroradiology. 2023;65:121–9. [DOI] [PubMed]

109.

Kim YZ, Kim CY, Lim DH. The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res Treat. 2022;10:83–93. [DOI] [PubMed] [PMC]

110.

Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979;5:1733–40. [DOI] [PubMed]

111.

Salazar OM, VanHoutte PJ, Bennett JM, Rubin P, Wheeler KT. High-dose radiation therapy with low-dose (pulsed) BCNU in malignant gliomas: an eastern cooperative oncology group (ECOG) report. Int J Radiat Oncol Biol Phys. 1982;8:915–9. [DOI] [PubMed]

112.

Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725–31. [DOI] [PubMed]

113.

Chen JC, Girvigian MR. Stereotactic radiosurgery: instrumentation and theoretical aspects—part 1. Perm J. 2005;9:23–6. [DOI] [PubMed] [PMC]

114.

Yanagihara TK, Saadatmand HJ, Wang TJ. Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. J Neurooncol. 2016;130:397–411. [DOI] [PubMed]

115.

Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys. 2015;91:109–15. [DOI] [PubMed]

116.

Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol. 2016;118:35–42. [DOI] [PubMed]

117.

Kong DS, Lee JI, Park K, Kim JH, Lim DH, Nam DH. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer. 2008;112:2046–51. [DOI] [PubMed]

118.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343–9. [DOI] [PubMed] [PMC]

119.

Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, et al. Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2016;6:217–25. [DOI] [PubMed]

120.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al.; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–29. Erratum in: Lancet Oncol. 2017;18:e642. [DOI] [PubMed]

121.

Sepúlveda-Sánchez JM, Muñoz Langa J, Arráez MÁ, Fuster J, Hernández Laín Á, Reynés G, et al. Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Clin Transl Oncol. 2018;20:108–9. Erratum for: Clin Transl Oncol. 2018;20:3–15. [DOI]

122.

Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, et al. Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013;39:125–35. [DOI] [PubMed]

123.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. [DOI] [PubMed]

124.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66. [DOI] [PubMed]

125.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al.; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393:678–88. [DOI]

126.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32. [DOI] [PubMed]

127.

Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40:403–26. [DOI] [PubMed]

128.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5. [DOI] [PubMed] [PMC]

129.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708. [DOI] [PubMed] [PMC]

130.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22. [DOI] [PubMed]

131.

Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 2013;7:CMO.S8503. [DOI] [PubMed] [PMC]

132.

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12:1300–10. [DOI] [PubMed] [PMC]

133.

Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101:1986–94. [DOI] [PubMed] [PMC]

134.

Verhoeff JJC, Lavini C, van Linde ME, Stalpers LJA, Majoie CBLM, Reijneveld JC, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21:1723–7. [DOI] [PubMed]

135.

Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol. 2014;116:533–41. [DOI] [PubMed] [PMC]

136.

Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010;12:508–16. [DOI] [PubMed] [PMC]

137.

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954–63. [DOI] [PubMed]

138.

Armstrong TS, Gilbert MR. Chemotherapy of astrocytomas: an overview. Semin Oncol Nurs. 1998;14:18–25. [DOI] [PubMed]

139.

Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–97. [DOI] [PubMed]

140.

Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013–21. [DOI] [PubMed]

141.

Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321–4. [DOI] [PubMed]

142.

Grimm SA, Chamberlain MC. State of the art and perspectives in the treatment of glioblastoma. CNS Oncol. 2012;1:49–70. [DOI] [PubMed] [PMC]

143.

Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol. 2009;185:235–40. [DOI] [PubMed]

144.

Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017;133:455–67. [DOI] [PubMed]

145.

Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, et al. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. J Neurooncol. 2018;137:439–46. [DOI] [PubMed]

146.

Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021;16:36. [DOI]

147.

De Leeuw BI, Van Baarsen KM, Snijders TJ, Robe PAJT. Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis. Neurooncol Adv. 2019;1:vdz032. [DOI] [PubMed] [PMC]

148.

Bonfield CM, Steinbok P. Pediatric cerebellar astrocytoma: a review. Childs Nerv Syst. 2015;31:1677–85. [DOI] [PubMed]

149.

Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20:S2–8. [DOI] [PubMed] [PMC]

150.

Dimou J, Beland B, Kelly J. Supramaximal resection: a systematic review of its safety, efficacy and feasibility in glioblastoma. J Clin Neurosci. 2020;72:328–34. [DOI] [PubMed]

151.

Di Carlo DT, Duffau H, Cagnazzo F, Benedetto N, Morganti R, Perrini P. IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis. Neurosurg Rev. 2020;43:383–95. [DOI] [PubMed]

152.

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, et al. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract. 2019;6:249–58. [DOI] [PubMed] [PMC]

153.

Nagoshi N, Tsuji O, Suzuki S, Nori S, Yagi M, Okada E, et al. Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma. Spinal Cord. 2022;60:216–22. [DOI] [PubMed]

154.

Ogunlade J, Wiginton JG 4th, Elia C, Odell T, Rao SC. Primary spinal astrocytomas: a literature review. Cureus. 2019;11:e5247. [DOI] [PubMed] [PMC]

155.

Khalafallah AM, Rakovec M, Bettegowda C, Jackson CM, Gallia GL, Weingart JD, et al. A crowdsourced consensus on supratotal resection versus gross total resection for anatomically distinct primary glioblastoma. Neurosurgery. 2021;89:712–9. [DOI] [PubMed] [PMC]

156.

Jackson C, Choi J, Khalafallah AM, Price C, Bettegowda C, Lim M, et al. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol. 2020;148:419–31. [DOI] [PubMed]

157.

Barajas RF Jr, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012;14:942–54. [DOI] [PubMed] [PMC]

158.

Eidel O, Burth S, Neumann JO, Kieslich PJ, Sahm F, Jungk C, et al. Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One. 2017;12:e0169292. [DOI] [PubMed] [PMC]

159.

Kubben PL, Wesseling P, Lammens M, Schijns OE, Ter Laak-Poort MP, van Overbeeke JJ, et al. Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastoma. Surg Neurol Int. 2012;3:158. [DOI] [PubMed] [PMC]

160.

Haddad AF, Young JS, Morshed RA, Berger MS. FLAIRectomy: resecting beyond the contrast margin for glioblastoma. Brain Sci. 2022;12:544. [DOI] [PubMed] [PMC]

161.

Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg. 2016;124:977–88. [DOI] [PubMed]

162.

Vivas-Buitrago T, Domingo RA, Tripathi S, De Biase G, Brown D, Akinduro OO, et al. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg. 2021;136:1–8. [DOI] [PubMed] [PMC]

163.

Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, et al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol. 2017;135:129–39. [DOI] [PubMed]

164.

Tripathi S, Vivas-Buitrago T, Domingo RA, Biase GD, Brown D, Akinduro OO, et al. IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model. J Neurosurg. 2022;136:1567–75. [DOI] [PubMed]

165.

Di L, Shah AH, Mahavadi A, Eichberg DG, Reddy R, Sanjurjo AD, et al. Radical supramaximal resection for newly diagnosed left-sided eloquent glioblastoma: safety and improved survival over gross-total resection. J Neurosurg. 2022;138:62–9. [DOI] [PubMed]

166.

Glenn CA, Baker CM, Conner AK, Burks JD, Bonney PA, Briggs RG, et al. An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg. 2018;114:e747–55. [DOI] [PubMed]

167.

Lopez-Rivera V, Dono A, Lewis CT, Chandra A, Abdelkhaleq R, Sheth SA, et al. Extent of resection and survival outcomes of geriatric patients with glioblastoma: is there benefit from aggressive surgery? Clin Neurol Neurosurg. 2021;202:106474. [DOI] [PubMed]

168.

Shah AH, Mahavadi A, Di L, Sanjurjo A, Eichberg DG, Borowy V, et al. Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol. 2020;148:501–8. [DOI] [PubMed] [PMC]

169.

Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R. Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park). 2019;33:91–100. [PubMed] [PMC]

170.

Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry. 2021;92:1103–11. [DOI] [PubMed]

171.

Matsumae M, Nishiyama J, Kuroda K. Intraoperative MR imaging during glioma resection. Magn Reson Med Sci. 2022;21:148–67. [DOI] [PubMed] [PMC]

172.

Coburger J, Scheuerle A, Kapapa T, Engelke J, Thal DR, Wirtz CR, et al. Sensitivity and specificity of linear array intraoperative ultrasound in glioblastoma surgery: a comparative study with high field intraoperative MRI and conventional sector array ultrasound. Neurosurg Rev. 2015;38:499–509. [DOI] [PubMed]

173.

Tanaka S, Tashiro T, Gomi A, Takanashi J, Ujiie H. Sensitivity and specificity in transcranial motor-evoked potential monitoring during neurosurgical operations. Surg Neurol Int. 2011;2:111. [DOI] [PubMed] [PMC]

174.

Traylor JI, Pernik MN, Sternisha AC, McBrayer SK, Abdullah KG. Molecular and metabolic mechanisms underlying selective 5-aminolevulinic acid-induced fluorescence in gliomas. Cancers (Basel). 2021;13:580. [DOI] [PubMed] [PMC]

175.

Smith EJ, Gohil K, Thompson CM, Naik A, Hassaneen W. Fluorescein-guided resection of high grade gliomas: a meta-analysis. World Neurosurg. 2021;155:181–8.e7. [DOI] [PubMed]

176.

Gandhi S, Tayebi Meybodi A, Belykh E, Cavallo C, Zhao X, Syed MP, et al. Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis. Front Oncol. 2019;9:620. [DOI] [PubMed] [PMC]

177.

Zhang N, Tian H, Huang D, Meng X, Guo W, Wang C, et al. Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant gliomas: our first 38 cases experience. Biomed Res Int. 2017;2017:7865747. Erratum in: Biomed Res Int. 2018;2018:6348625. [DOI] [PubMed] [PMC]

178.

Naik A, Smith EJ, Barreau A, Nyaeme M, Cramer SW, Najafali D, et al. Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for resection of high-grade gliomas: a systematic review and network meta-analysis. J Clin Neurosci. 2022;98:240–7. [DOI] [PubMed]

179.

Zeppa P, De Marco R, Monticelli M, Massara A, Bianconi A, Di Perna G, et al. Fluorescence-guided surgery in glioblastoma: 5-ALA, SF or both? Differences between fluorescent dyes in 99 consecutive cases. Brain Sci. 2022;12:555. [DOI] [PubMed] [PMC]

180.

Clavreul A, Aubin G, Delion M, Lemée JM, Ter Minassian A, Menei P. What effects does awake craniotomy have on functional and survival outcomes for glioblastoma patients? J Neurooncol. 2021;151:113–21. [DOI] [PubMed]

181.

Sacko O, Lauwers-Cances V, Brauge D, Sesay M, Brenner A, Roux FE. Awake craniotomy vs surgery under general anesthesia for resection of supratentorial lesions. Neurosurgery. 2011;68:1192–9. [DOI] [PubMed]

182.

Gravesteijn BY, Keizer ME, Vincent AJPE, Schouten JW, Stolker RJ, Klimek M. Awake craniotomy versus craniotomy under general anesthesia for the surgical treatment of insular glioma: choices and outcomes. Neurol Res. 2018;40:87–96. [DOI] [PubMed]

183.

Suarez-Meade P, Marenco-Hillembrand L, Prevatt C, Murguia-Fuentes R, Mohamed A, Alsaeed T, et al. Awake vs. asleep motor mapping for glioma resection: a systematic review and meta-analysis. Acta Neurochir (Wien). 2020;162:1709–20. [DOI] [PubMed]

184.

Zhang JJY, Lee KS, Voisin MR, Hervey-Jumper SL, Berger MS, Zadeh G. Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020;2:vdaa111. [DOI] [PubMed] [PMC]

185.

Zigiotto L, Annicchiarico L, Corsini F, Vitali L, Falchi R, Dalpiaz C, et al. Effects of supra-total resection in neurocognitive and oncological outcome of high-grade gliomas comparing asleep and awake surgery. J Neurooncol. 2020;148:97–108. [DOI] [PubMed]

186.

Bu LH, Zhang J, Lu JF, Wu JS. Glioma surgery with awake language mapping versus generalized anesthesia: a systematic review. Neurosurg Rev. 2021;44:1997–2011. [DOI] [PubMed]

187.

Moiraghi A, Roux A, Peeters S, Pelletier JB, Baroud M, Trancart B, et al. Feasibility, safety and impact on overall survival of awake resection for newly diagnosed supratentorial IDH-wildtype glioblastomas in adults. Cancers (Basel). 2021;13:2911. [DOI] [PubMed] [PMC]

188.

Lu VM, Phan K, Rovin RA. Comparison of operative outcomes of eloquent glioma resection performed under awake versus general anesthesia: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;169:121–7. [DOI] [PubMed]

189.

Gerritsen JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, Jessurun CAC, Versyck G, et al. Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study. Lancet Oncol. 2022;23:802–17. [DOI] [PubMed]

190.

Gerritsen JKW, Dirven CMF, De Vleeschouwer S, Schucht P, Jungk C, Krieg SM, et al. The PROGRAM study: awake mapping versus asleep mapping versus no mapping for high-grade glioma resections: study protocol for an international multicenter prospective three-arm cohort study. BMJ Open. 2021;11:e047306. Erratum in: BMJ Open. 2022;12:e047306corr1. [DOI] [PubMed] [PMC]

191.

Gerritsen JKW, Klimek M, Dirven CMF, Hoop EO, Wagemakers M, Rutten GJM, et al. The SAFE-trial: Safe surgery for glioblastoma multiforme: awake craniotomy versus surgery under general anesthesia. Study protocol for a multicenter prospective randomized controlled trial. Contemp Clin Trials. 2020;88:105876. [DOI] [PubMed]

192.

Wu A, Lim M. The challenges and future of immunotherapy for gliomas. Cancer J. 2021;27:371–8. [DOI] [PubMed]

193.

Liang M, Gao C, Wang Y, Gong W, Fu S, Cui L, et al. Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Drug Deliv. 2018;25:1652–63. [DOI] [PubMed] [PMC]

194.

Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144–51. [DOI] [PubMed]

195.

Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14:358–71. [DOI] [PubMed] [PMC]

196.

Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020;11:5687. [DOI] [PubMed] [PMC]

197.

Shah AH, Heiss JD. Neurosurgical clinical trials for glioblastoma: current and future directions. Brain Sci. 2022;12:787. [DOI] [PubMed] [PMC]

198.

Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, et al. First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg. 2019;130:476–85. [DOI] [PubMed]

199.

Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019;8:1398. [DOI] [PubMed] [PMC]

200.

McNutt M. Cancer immunotherapy. Science. 2013;342:1417. [DOI] [PubMed]

201.

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. [DOI] [PubMed] [PMC]

202.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61. [DOI] [PubMed] [PMC]

203.

Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41:142. [DOI] [PubMed] [PMC]

204.

Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017;9:eaaf2968. [DOI] [PubMed]

205.

Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:765. Erratum for: Nat Rev Cancer. 2017;17:709–24. [DOI] [PubMed]

206.

Caccese M, Padovan M, D’Avella D, Chioffi F, Gardiman MP, Berti F, et al. Anaplastic astrocytoma: state of the art and future directions. Crit Rev Oncol Hematol. 2020;153:103062. [DOI] [PubMed]

207.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAF^V600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018;36:3477–84. [DOI] [PubMed] [PMC]

208.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25:4888–97. [DOI] [PubMed]

209.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397–405. [DOI] [PubMed]